Company newsCompany release

Intellia Therapeutics NTLA

Intellia Therapeutics presents additional lonvo-z data at ACAAI 2026

Intellia Therapeutics also plans an investor webcast on November 12, 2026, at 10:00 a.m. ET on the data and its launch preparations.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Intellia Therapeutics said on November 12, 2026, that it had highlighted data from seven presentations on lonvoguran ziclumeran (lonvo-z) at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona.

The company said it will host an investor webcast on the same day at 10:00 a.m. ET to review certain of the data, hear from key opinion leaders and discuss preparations for a planned commercial launch of lonvo-z in hereditary angioedema (HAE).

Key facts

Location
Phoenix, Arizona
Presentations
Seven at ACAAI 2026 Annual Scientific Meeting
Investor webcast
November 12, 2026, 10:00 a.m. ET

All NTLA news

Source: The company's release on GlobeNewswire, November 12, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

Intellia Therapeutics first, then the newest

All company news